Detalhe da pesquisa
1.
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Dermatol Ther
; 35(4): e15303, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984792
2.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
N Engl J Med
; 367(23): 2204-13, 2012 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23121378
3.
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
Lancet Respir Med
; 8(10): 987-999, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653075
4.
Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Int J Chron Obstruct Pulmon Dis
; 13: 3923-3936, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30584293
5.
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
J Renin Angiotensin Aldosterone Syst
; 13(3): 387-93, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22333485